We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept


Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, diseases and pain. 
Product Indication Dosage form Strength
Depression Tablets 10 and 20 mg
Buprenorphine Opioid dependence 0,4/ 1/ 2/ 4/ 6 & 8 mg sublingual films
Eslicarbazepine Epilepsy Tablets 400 and 1200 mg
Fluoxetine Depression Tablets 10 and 20 mg
Lamotrigine Lamotrigine XR tablets 25/ 50/ 100/ 200 & 300 mg
Levetiracetam Epilepsy XR tablets 1; 1,5; 2 and 3 g XR coated minitablets
Pyridostigmine Myasthenia gravis Film-coated tablets 60 mg
Pyridostigminie Myasthenia gravis XR tablets 180 mg
Quetiapine * Psychosis, schizophrenia, bipolar disoder Orodispersable tablets 25 and 50 mg
Rotigotine Parkinson disease & restless legs Patches 1, 2, 3, 4, 6 and 8 mg/24h

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.

© Neuraxpharm / LESVI. All rights reserved.